Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen cut shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a buy rating to a hold rating in a report released on Saturday,Wall Street Zen reports.

A number of other equities analysts have also recently weighed in on AUPH. Royal Bank Of Canada upped their price objective on shares of Aurinia Pharmaceuticals from $16.00 to $18.00 and gave the stock a “sector perform” rating in a research report on Monday, November 2nd. TD Cowen lifted their target price on shares of Aurinia Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, October 21st. Bloom Burton raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Zacks Research cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 21st. Finally, Weiss Ratings upgraded shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

Aurinia Pharmaceuticals Stock Up 1.5%

Aurinia Pharmaceuticals stock opened at $16.46 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.12 and a quick ratio of 4.97. The stock has a market capitalization of $2.21 billion, a PE ratio of 7.19 and a beta of 1.40. The business has a 50 day simple moving average of $16.48 and a 200-day simple moving average of $15.68. Aurinia Pharmaceuticals has a 12 month low of $13.52 and a 12 month high of $19.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Friday, October 30th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.01. Aurinia Pharmaceuticals had a return on equity of 22.99% and a net margin of 97.68%. The firm had revenue of $83.70 million for the quarter, compared to analyst estimates of $83.61 million. On average, analysts anticipate that Aurinia Pharmaceuticals will post 0.97 EPS for the current fiscal year.

Institutional Trading of Aurinia Pharmaceuticals

Several large investors have recently made changes to their positions in AUPH. Bank of America Corp DE acquired a new stake in shares of Aurinia Pharmaceuticals in the second quarter valued at about $3,820,000. Legal & General Group Plc purchased a new position in shares of Aurinia Pharmaceuticals in the second quarter worth about $1,747,000. OMERS ADMINISTRATION Corp acquired a new position in Aurinia Pharmaceuticals during the second quarter worth about $1,573,000. Man Group plc acquired a new position in Aurinia Pharmaceuticals during the second quarter worth about $1,424,000. Finally, PDT Partners LLC purchased a new stake in shares of Aurinia Pharmaceuticals in the second quarter valued at approximately $4,505,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s principal product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with other immunosuppressive therapies to treat adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Voclosporin was approved by the U.S. Food and Drug Administration in 2021, making Lupkynis the first oral therapy specifically approved in the United States for adult patients with active lupus nephritis.